Overview:
ADCs form a group of new pharmaceutically active molecules with significant potential benefits for patients. Recent structural advancements have further enhanced their pharmaceutical appeal, leading to increased development efforts by many companies. However, analysing ADCs presents unique challenges, requiring both ligand binding assays and LC-MS/MS assays.
During this webinar hosted by Bioanalysis Zone, ICON's experts will discuss the complexities of ADC assays and how they can be best optimised.
Topics will include:
- Bioanalytical considerations for selecting the right assays
- Bioanalytical development and validation parameters specific to ADCs
Speakers:
Chairi Misrielal
Chairi has a bachelor's degree in Pharmacy and a master’s degree in Medical Pharmaceutical Drug Innovation. Following a PhD scholarship, she successfully defended her thesis focused on autophagy and multiple sclerosis. In 2022, Chairi joined ICON as a Project Manager, where she utilises her expertise to lead and support innovative projects within the bioanalytical laboratories.
Kevin Roback
Kevin is a Principal Scientist in the method development and validation group at ICON Bioanalytical Laboratories. He holds a bachelor’s degree in mathematics and neuroscience and began his career at ICON in 2018. Kevin's initial focus was on sample analysis but has since shifted to developing and validating ligand binding assays to assess the pharmacokinetics, pharmacodynamics and immunogenicity of large molecule therapeutics and biomarkers.
Mackenzie Bentley
Mackenzie has a bachelor's degree in Chemistry and has been working in the bioanalytical space for over 10 years. Her focus has been development, validation and bioanalysis of small and large molecule assays. Mackenzie has worked for ICON plc for 2 years as the Bioanalytical Services Manager over LC–MS, supporting method validation and bioanalysis.